칸데사르탄 실렉세틸 고체분산체 개발 및 평가

• 영문명: Development and Evaluation of Candesartan Cilexetil Solid Dispersion
• 발행기관: 대한약학회
• 저자명: 임수빈(Su Bin Lim) 최진석(Jin-Seok Choi)
• 간행물 정보: 『약학회지』제69권 제1호(2025년), 75~82쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2025.02.28

국문 초록

Candesartan cilexetil (CDST) is belongs to the Biopharmaceutics Classification System (BCS) class II and is widely used to treat hypertension. The commercial product as Atacand®Tab contains 16 mg of CDST out of a total weight of 130 mg. The purpose of this study is to solubilize and stabilize CDST, and develop a CDST solid dispersion (SD) containing a carrier and a polymer without a weak base. Therefore, a CDST-SD was developed using a solvent evaporation method. The dissolution (%) of CDST in final formulation (SB-SD1) improved by 4.1-, 21.6-, and 19.8-fold compared to that of Atacand®Tab at 60 min in pH 1.2 media, distilled water (DW), and pH 6.8 buffer, respectively. The physicochemical properties of the SB-SD1 formulation changed the melting point and crystallinity of CDST. Additionally, stability for six months was secured. In conclusion, the SB-SD1 formulation improved the dissolution of CDST and secured stability due to changes in physicochemical properties.

목차

서 론(Introduction)

방 법(Methods)

결과 및 고찰(Results and Discussion)

결 론(Conclusion)

감사의 말씀(Acknowledgment)

Conflict of Interest

References

키워드

Candesartan cilexetil (CDST) Kolliphor®P188 Neusilin®UFL2 Solvent evaporation method Dissolution Stability